Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease

• Published in: JAMA neurology Vol. 73; no. 5; p. 561
• Main Authors: Tarawneh, Rawan, D'Angelo, Gina, Crimmins, Dan, Herries, Elizabeth, Griest, Terry, Fagan, Anne M, Zipfel, Gregory J, Ladenson, Jack H, Morris, John C, Holtzman, David M
• Format: Journal Article
• Language: English
• Published: United States 01.05.2016
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - complications; Alzheimer Disease - diagnosis; Amyloid beta-Peptides - cerebrospinal fluid; Aniline Compounds - metabolism; Apolipoprotein E4 - genetics; Atrophy - pathology; Cognition Disorders - diagnosis; Cognition Disorders - etiology; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Humans; Independent Living; Male; Middle Aged; Neurocalcin - cerebrospinal fluid; Neurogranin - cerebrospinal fluid; Neuropsychological Tests; Peptide Fragments - cerebrospinal fluid; Positron-Emission Tomography; Predictive Value of Tests; ROC Curve; Severity of Illness Index; Statistics, Nonparametric; tau Proteins - cerebrospinal fluid; Thiazoles - metabolism

Synaptic loss is an early pathologic substrate of Alzheimer disease (AD). Neurogranin is a postsynaptic neuronal protein that has demonstrated utility as a cerebrospinal fluid (CSF) marker of synaptic loss in AD. To investigate the diagnostic and prognostic utility of CSF neurogranin levels in a lar...